| [1] |
Duncan BB, Magliano DJ, Boyko EJ. IDF Diabetes Atlas 11th edition 2025: global prevalence and projections for 2050[J]. Nephrol Dial Transplant, 2025, 41(1): 7-9. doi:10.1093/ndt/gfaf177
|
| [2] |
Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies[J]. Bmj, 2006, 332(7533): 73-8. doi:10.1136/bmj.38678.389583.7C
|
| [3] |
An YL, Zhang P, Wang JP, et al. Cardiovascular and all-cause mortality over a 23-year period among Chinese with newly diagnosed diabetes in the da Qing IGT and diabetes study[J]. Diabetes Care, 2015, 38(7): 1365-71. doi:10.2337/dc14-2498
|
| [4] |
Low Wang CC, Hess CN, Hiatt WR, et al. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus–mechanisms, management, and clinical considerations[J]. Circulation, 2016, 133(24): 2459-502. doi:10.1161/CIRCULATIONAHA.116.022194
|
| [5] |
Valmadrid CT, Klein R, Moss SE, et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus[J]. Arch Intern Med, 2000, 160(8): 1093. doi:10.1001/archinte.160.8.1093
|
| [6] |
Howard BV, Magee MF. Diabetes and cardiovascular disease[J]. Curr Atheroscler Rep, 2000, 2(6): 476-81. doi:10.1007/s11883-000-0046-8
|
| [7] |
Kishor S, Chen JR, Zhang Y, et al. Interaction of proteinuria and diabetes on the risk of cardiovascular events: a prospective cohort CKD-ROUTE study[J]. BMC Public Health, 2024, 24(1): 3192. doi:10.1186/s12889-024-20715-2
|
| [8] |
Liu JE, Robbins DC, Palmieri V, et al. Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes[J]. J Am Coll Cardiol, 2003, 41(11): 2022-8. doi:10.1016/S0735-1097(03)00403-0
|
| [9] |
Nakamura K, Miyoshi T, Yoshida M, et al. Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus[J]. Int J Mol Sci, 2022, 23(7): 3587. doi:10.3390/ijms23073587
|
| [10] |
Li Y, Du YH, Liu Y, et al. Cardiomyocyte-derived small extracellular vesicle: a new mechanism driving diabetic cardiac fibrosis and cardiomyopathy[J]. Theranostics, 2024, 14(15): 5926-44. doi:10.7150/thno.99507
|
| [11] |
Jia GH, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity[J]. Circ Res, 2018, 122(4): 624-38. doi:10.1161/circresaha.117.311586
|
| [12] |
Liu JY, Liu Y, Chen L, et al. Glucagon-like peptide-1 analog liraglutide protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway[J]. J Diabetes Res, 2013, 2013: 630537. doi:10.1155/2013/630537
|
| [13] |
Zhang Y, Ling YN, Yang L, et al. Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat[J]. Mol Cell Endocrinol, 2017, 448: 98-107. doi:10.1016/j.mce.2017.03.029
|
| [14] |
李京娟, 李凡凡, 牛 璐, 等. 司美格鲁肽对高糖诱导的心肌成纤维细胞增殖的作用研究[J]. 南方医科大学学报, 2023, 43(11): 1935-40. doi:10.12122/j.issn.1673-4254.2023.11.14
|
| [15] |
Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody[J]. Endocrinology, 2014, 155(4): 1280-90. doi:10.1210/en.2013-1934
|
| [16] |
Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways[J]. Circulation, 2008, 117(18): 2340-50. doi:10.1161/CIRCULATIONAHA.107.739938
|
| [17] |
Zhao T, Chen HQ, Xu F, et al. Liraglutide alleviates cardiac fibrosis through inhibiting P4hα‑1 expression in STZ-induced diabetic cardiomyopathy[J]. Acta Biochim Biophys Sin, 2019, 51(3): 293-300. doi:10.1093/abbs/gmy177
|
| [18] |
Huynh K, Kiriazis H, Du XJ, et al. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes[J]. Diabetologia, 2012, 55(5): 1544-53. doi:10.1007/s00125-012-2495-3
|
| [19] |
Huynh K, McMullen JR, Julius TL, et al. Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy[J]. Diabetes, 2010, 59(6): 1512-20. doi:10.2337/db09-1456
|
| [20] |
Ji YQ, Zhao Z, Cai TZ, et al. Liraglutide alleviates diabetic cardio-myopathy by blocking CHOP-triggered apoptosis via the inhibition of the IRE-α pathway[J]. Mol Med Rep, 2014, 9(4): 1254-8. doi:10.3892/mmr.2014.1956
|
| [21] |
Seferović PM, Paulus WJ, Rosano G, et al. Diabetic myocardial disorder. a clinical consensus statement of the heart failure association of the ESC and the ESC working group on myocardial & pericardial diseases[J]. Eur J Heart Fail, 2024, 26(9): 1893-903. doi:10.1002/ejhf.3347
|
| [22] |
Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease[J]. Circ Res, 2020, 126(11): 1501-25. doi:10.1161/circresaha.120.315913
|
| [23] |
Balogh DB, Wagner LJ, Fekete A. An overview of the cardioprotective effects of novel antidiabetic classes: focus on inflammation, oxidative stress, and fibrosis[J]. Int J Mol Sci, 2023, 24(9): 7789. doi:10.3390/ijms24097789
|
| [24] |
Liu MR, López de Juan Abad B, Cheng K. Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies[J]. Adv Drug Deliv Rev, 2021, 173: 504-19. doi:10.1016/j.addr.2021.03.021
|
| [25] |
Helmstädter J, Frenis K, Filippou K, et al. Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular pro-tection by liraglutide in mice with experimental arterial hypertension[J]. Arterioscler Thromb Vasc Biol, 2020, 40(1): 145-58. doi:10.1161/atv.0000615456.97862.30
|
| [26] |
Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice[J]. Diabetes, 2009, 58(4): 975-83. doi:10.2337/db08-1193
|
| [27] |
Zhu YX, Zhang W, Qu HL, et al. Liraglutide alleviates diabetic cardiomyopathy in streptozotocin-induced diabetic rats by enhancing mitophagy mediated by the AMPK-Parkin signaling pathway[J]. World J Diabetes, 2025, 16(12): 1125-33. doi:10.4239/wjd.v16.i12.112423
|
| [28] |
Wang XW, Zhang FX, Yang F, et al. Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro [J]. Acta Pharmacol Sin, 2016, 37(10): 1349-58. doi:10.1038/aps.2016.72
|
| [29] |
Eid RA, Khalil MA, Alkhateeb MA, et al. Exendin-4 attenuates remodeling in the remote myocardium of rats after an acute myocardial infarction by activating β‑arrestin-2, protein phosp-hatase 2A, and glycogen synthase kinase-3 and inhibiting β-catenin[J]. Cardiovasc Drugs Ther, 2021, 35(6): 1095-110. doi:10.1007/s10557-020-07006-9
|
| [30] |
Wang LD, Xin QQ, Wang Y, et al. Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials[J]. Pharmacol Res, 2021, 171: 105765. doi:10.1016/j.phrs.2021.105765
|
| [31] |
Kuo CY, Tsou SH, Kornelius E, et al. The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy[J]. Cell Mol Life Sci, 2025, 82(1): 39. doi:10.1007/s00018-024-05558-9
|
| [32] |
Noyan-Ashraf MH, Shikatani EA, Schuiki I, et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity[J]. Circulation, 2013, 127(1): 74-85. doi:10.1161/CIRCULATIONAHA.112.091215
|